Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Inclusion Criteria:

- Willing and able to provide written informed consent

- HCV RNA ≥ 10^4 IU/mL at screening

- HCV genotype 1, 2, 4, 5, 6, or indeterminate assessed at screening by the central
laboratory

- Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy

- Classification as treatment naive or treatment experienced

- Males and females of childbearing potential who engage in heterosexual intercourse
must agree to use protocol specified method(s) of contraception

Exclusion Criteria:

- Current or prior history of clinically-significant illness (other than HCV) or any
other major medical disorder that may interfere with treatment, assessment, or
compliance with the protocol; individuals currently under evaluation for a potentially
clinically-significant illness (other than HCV) are also excluded.

- Screening ECG with clinically significant abnormalities

- Laboratory results outside of acceptable ranges at Screening

- Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A
inhibitor

- Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)